EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway

Oncotarget

Volumn 7, Issue 30, 2016, Pages 47938-47953

  Yin, Xiuxiu ^a,b   Fang, Shuang ^c   Wang, Mei ^d   Wang, Qiang ^e   Fang, Rui ^a   Chen, Jie ^a  

^a SHANDONG UNIVERSITY   (China)

^b The NO1 People's Hospital of Jining   (China)

^c GEORGETOWN UNIVERSITY   (United States)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

EFEMP1; EMT; Invasion; Metastasis; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR CONTAINING FIBULIN LIKE EXTRACELLULAR MATRIX PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCLEROPROTEIN; UNCLASSIFIED DRUG; EFEMP1 PROTEIN, HUMAN; ONCOPROTEIN;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LENTIVIRINAE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARIAN CANCER CELL LINE; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84982854568     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10296     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
2. Januchowski R, Zawierucha P, Rucinski M, Nowicki M, Zabel M. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int. 2014:365867.
3. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009; 4:287-313.
4. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9:415-428.
5. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331:1559-1564.
6. de Vega S, Iwamoto T, Yamada Y. Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life. 2009; 66:1890-1902.
7. Canqemi C, Hansen ML, Arqraves WS, Rasmussen LM. Fibulins and their role in cardiovascular biology and disease. Adv Clin Chem. 2014; 67:245-265.
8. Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer: friend or foe? Trends Mol Med. 2005; 11:336-340.
9. Song EL, Hou YP, Yu SP, Chen SG, Huang JT, Luo T, Kong LP. EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol. 2011; 121:174-180.
10. Seeliger H, Camai P, Ischenko I, Kleespies A, De Toni EN, Thieme SE. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res. 2009; 7:189-198.
11. Hu B, Thirtamara-Raiamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res. 2009; 7:1756-1770.
12. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 2009; 124:1727-1735.
13. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol. 2010; 222:367-379.
14. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 2011; 10:123.
15. Chen J, Wei D, Zhao Y, Liu X, Zhang J. Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma. Plos One.2013; 8: e78783.
16. Obaya AJ, Rua S, Moncada-Pazos A, Cal S. The dual role of fibulins in tumorigenesis. Cancer Lett. 2012; 325:132-8.
17. Arechederra M, Priego N, Vázquez-Carballo A, Sequera C, Gutiérrez-Uzquiza Á, Cerezo-Guisado MI, Ortiz-Rivero S, Roncero C, Cuenda A, Guerrero C, Porras A. p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: role in migration and invasion. J Biol Chem. 2015; 290:4383-97.
18. Nandhu MS, Hu B, Cole SE, Erdreich-Epstein A, Rodriguez-Gil DJ, Viapiano MS. Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas. Cancer Res. 2014; 74:5435-48.
19. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, Mora ME, Nuovo GJ, Cole SE, Viapiano MS. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 2012; 72:3873-85.
20. Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z, Zhang L. Fibulin-3 suppresses Wnt/β-catenin signaling and lung cancer invasion. Carcinogenesis. 2014; 35:1707-16.
21. Chen L, Sun B, Zhang S, Zhao X, He Y, Zhao S, Lin T, Li X. Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma. Oncol Rep. 2009; 21:917-23.
22. Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, Baselga J, Scaltriti M. AKT signaling in ERBB2-amplified breast cancer. Pharmacol Ther. 2015.
23. Kim IG, Kim SY, Choi SI, Lee JH, Kim KC, Cho EW. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene. 2014; 33:3908-17.
24. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN, Faktorova D, Jauch KW, Bruns CJ. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem. 2009; 390:1293-302.
25. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014; 3:17.
26. Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT. 2014; 3:e28975.
27. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29:4741-4751.
28. Chen J, Zhang J, Zhao Y, Li J, Fu M. Integrin beta3 downregulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol 2009; 135:909-17.